新闻动态
LC Labs/M-2433 Mocetinostat, Free Base, >99%/M-2433/25 mg
2025-11-17
- Mocetinostat selectively inhibits histone deacetylases (HDACs) 1-3 and 11 at submicromolar concentrations. It blocks cancer cell proliferation in vitro and has significant antitumor activity in vivo. Zhou, N., et al. \"Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.\" J. Med. Chem. 51: 4072-4075 (2008).
- Mocetinostat induces hyperacetylation of histones, causes expression of the tumor suppressor protein p21(WAF1/CIP1), and inhibits proliferation of human cancer cells growing in culture. Raeppel, S., et al. \"SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).\" Bioorg. Med. Chem. Lett. 19: 644-649 (2009).
- Mocetinostat demonstrated antitumor activity against hematological and lymphoproliferative cancers. Le Tourneau, C. and Siu, L.L. \"Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor.\" Expert Opin. Investig. Drugs 17: 1247-1254 (2008).
- Mocetinostat dose-dependently inhibited HDAC activity in several human cancer cell lines and in human peripheral white blood cells. The inhibitory effect of mocetinostat lasted for at least 8 hours in mice and 48 hours in patients with solid tumors. Bonfils, C., et al. \"Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.\" Clin. Cancer Res. 14: 3441-3449 (2008).
- Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
Related Terms:
[MG-0103] [MGCD0103]M.W. 396.44C23H20N6O[726169-73-9]Storage
Store at or below -20 ºCSolubility
Soluble in DMSODisposal
A本文链接： https://www.ebiomall.cn/b117-discovery/info-1515985944.html
免责声明 本文仅代表作者个人观点，与本网无关。其创作性以及文中陈述文字和内容未经本站证实，对本文以及其中全部或者部分内容、文字的真实性、完整性、及时性本站不做任何保证或承诺，请读者仅作参考，并请自行核实相关内容。
版权声明 未经蚂蚁淘授权不得转载、摘编或利用其他方式使用上述作品。已经经本网授权使用作品的，应该授权范围内使用，并注明“来源：蚂蚁淘”。违反上述声明者，本网将追究其相关法律责任。
相关文章
2020-07-05
2020-07-17
2020-07-28
2020-08-06
2020-09-10
2020-09-19
2020-10-12
2020-11-02
2021-03-15
▍
品牌分类
▍
官网分类
